Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GLP-1 Compounding: Lilly Takes Advertising Complaints To NAD

Jan 30 2025

• By Sue Sutter

Woman on scale — Lilly is battling companies marketing compounded GLP-1 products for weight loss.

Related Content

Drug Advertising: NAD’s Clout In Rx Disputes Rising As It Builds Ties With Social Media Platforms, FDA

Apr 08 2024

ViiV Wants FDA, Not NAD, To Handle Dispute Over Its Dovato HIV Drug Ads

Apr 28 2023

Novartis’ Kisqali Consumer Promos Inappropriately Convey Superiority, NAD Finds In Unusual Ruling

Jan 19 2023

US FDA Takes Lilly’s Mounjaro, Zepbound Off Shortage List But Gives Compounding Grace Period

Dec 19 2024

Related Companies

Eli Lilly and Company

Novo Nordisk A/S

Novartis AG

More from Marketing & Advertising

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window